Percy H. Carter Sells 4,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider Percy H. Carter sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the transaction, the insider now owns 41,895 shares of the company’s stock, valued at $4,404,421.35. The transaction was disclosed in a filing with the SEC, which is available through this link.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded down $1.06 during mid-day trading on Friday, hitting $103.36. 183,637 shares of the company traded hands, compared to its average volume of 719,618. Blueprint Medicines Co. has a one year low of $43.89 and a one year high of $111.02. The stock has a market cap of $6.47 billion, a price-to-earnings ratio of -21.61 and a beta of 0.70. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76. The stock has a fifty day moving average price of $98.40 and a 200-day moving average price of $88.74.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.32. The business had revenue of $96.12 million during the quarter, compared to analyst estimates of $82.58 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. On average, equities analysts predict that Blueprint Medicines Co. will post -5.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

A number of hedge funds have recently made changes to their positions in BPMC. Covestor Ltd raised its holdings in Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 291 shares during the last quarter. Headlands Technologies LLC raised its holdings in Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 342 shares during the last quarter. Compass Wealth Management LLC bought a new stake in Blueprint Medicines during the 4th quarter valued at $69,000. Natixis bought a new stake in Blueprint Medicines during the 1st quarter valued at $73,000. Finally, Van ECK Associates Corp raised its holdings in Blueprint Medicines by 28.4% during the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 193 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. SVB Leerink raised shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and boosted their target price for the stock from $50.00 to $97.00 in a report on Monday, May 6th. Piper Sandler upped their price objective on shares of Blueprint Medicines from $78.00 to $104.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Citigroup boosted their target price on shares of Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research report on Friday, May 3rd. Stifel Nicolaus boosted their target price on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Stephens initiated coverage on shares of Blueprint Medicines in a research report on Tuesday, May 14th. They set an “overweight” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.00.

View Our Latest Stock Analysis on Blueprint Medicines

About Blueprint Medicines

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Featured Articles

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.